ANXA6 and prostate carcinoma: The data presented here suggest a potential role for CAFs to upregulate ANXA6 expression in early disease stages in prostate cancer, which promotes increased epithelial cell proliferation, suggesting the possibility of therapeutic targeting of this CAF-specific signalling mechanism.